Adma Biologics Inc. | Mid-cap | Healthcare
$18.21
0.28%
| Adma Biologics Stock Comparison:
Adma Biologics vs VertexAdma Biologics vs RegeneronAdma Biologics vs Blueprint MedicinesAdma Biologics vs Roivant SciencesAdma Biologics vs Bio-TechneAdma Biologics vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 426.5M
Gross Profit 219.6M 51.48%
Operating Income 139.0M 32.59%
Net Income 197.7M 46.35%

Balance Sheet Metrics

Total Assets 488.7M
Total Liabilities 139.7M
Shareholders Equity 349.0M
Debt to Equity 0.40

Cash Flow Metrics

Operating Cash Flow 119.0M
Free Cash Flow 110.1M

Revenue & Profitability Trend

Adma Biologics Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 426.5M 258.2M 154.1M 80.9M 42.2M
Cost of Goods Sold 206.9M 169.3M 118.8M 79.8M 61.3M
Gross Profit 219.6M 88.9M 35.3M 1.2M -19.1M
Operating Expenses 80.2M 66.6M 73.9M 58.8M 45.1M
Operating Income 139.0M 21.6M -39.4M -58.4M -64.9M
Pre-tax Income 125.7M -28.2M -65.9M -71.6M -75.7M
Income Tax -72.0M - - - -
Net Income 197.7M -28.2M -65.9M -71.6M -75.7M
EPS (Diluted) - -$0.13 -$0.33 -$0.51 -$0.88

Income Statement Trend

Adma Biologics Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 331.4M 257.0M 270.4M 208.7M 153.7M
Non-Current Assets 157.3M 72.2M 78.1M 67.5M 53.9M
Total Assets 488.7M 329.2M 348.5M 276.3M 207.7M
Liabilities
Current Liabilities 55.5M 49.8M 39.3M 30.4M 19.9M
Non-Current Liabilities 84.1M 144.2M 157.2M 104.7M 99.5M
Total Liabilities 139.7M 194.0M 196.5M 135.1M 119.4M
Equity
Total Shareholders Equity 349.0M 135.2M 152.0M 141.2M 88.2M

Balance Sheet Composition

Adma Biologics Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 197.7M -28.2M -65.9M -71.6M -75.7M
Operating Cash Flow 119.0M -25.9M -73.5M -117.9M -104.0M
Investing Activities
Capital Expenditures -8.2M -4.8M -13.9M -13.5M -12.7M
Investing Cash Flow -8.2M -4.8M -13.9M -13.5M -12.7M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow -65.8M -40.1M 108.7M 121.0M 143.9M
Free Cash Flow 110.1M 3.8M -73.4M -125.9M -114.7M

Cash Flow Trend

Adma Biologics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 21.27
Forward P/E 24.82
Price to Book 11.42
Price to Sales 9.29
PEG Ratio 24.82

Profitability Ratios

Profit Margin 45.01%
Operating Margin 30.38%
Return on Equity 78.45%
Return on Assets 22.06%

Financial Health

Current Ratio 6.58
Debt to Equity 21.96
Beta 0.47

Per Share Data

EPS (TTM) $0.84
Book Value per Share $1.57
Revenue per Share $1.95

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
adma 4.3B 21.27 11.42 78.45% 45.01% 21.96
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Blueprint Medicines 8.3B -120.00 24.19 -47.71% -27.70% 208.50
Roivant Sciences 7.8B 1.95 1.71 -12.54% 96.86% 1.93
Bio-Techne 7.9B 60.87 3.92 6.53% 10.89% 20.99

Financial data is updated regularly. All figures are in the company's reporting currency.